Vaccine

US7255867B2 · kind B2 · utility

Assignees

• ID Biomedical Corporation of Quebec · CA
• The Council of the Queensland Institute of Medical Research · AU

Inventors

• George H. Lowell · Baltimore, US
• George L White · Beaconsfield, CA
• Michael Batzloff · Calle de la Era, AU
• David S. Burt · Ajax, CA
• Tomas Leanderson · Lund, SE
• Michael Good · Forsayth, AU

Key dates

• Filing date: Nov 13, 2003
• Grant date: Aug 14, 2007
• Expiry date: Dec 30, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/6068
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.